Literature DB >> 23912800

Regulatory T cells in Behçet's disease: is there a correlation with disease activity? Does regulatory T cell type matter?

Eren Gündüz1, Hava Usküdar Teke, Nazife Sule Yaşar Bilge, Döndü Usküdar Cansu, Cengiz Bal, Cengiz Korkmaz, Zafer Gülbaş.   

Abstract

The aim of this study was to investigate the percentage of regulatory T cells and the correlation with clinical activity in Behçet's disease. Forty Behçet's disease (BD) patients, 18 males and 22 females, were included in the study. The patients were diagnosed according to the published BD criteria. Twenty age- and sex-matched volunteer healthy donors were also included. At the time of sampling, clinical activity was assessed for activity signs and symptoms according to the BD Current Activity Form. We considered active those patients with a clinical activity index equal to and/or above 2. Eleven patients had active disease and the remaining were considered as clinically inactive. We have studied the percentages of CD4+CD25+FOXP3+, CD4+CD25+ and CD4+FOXP3+regulatory T cells by flow cytometry and investigated the correlation with disease activity. Percentage of CD4+CD25+FOXP3+Treg in active patients was lower than clinically inactive patients and healthy controls. Percentage of CD4+CD25+Treg was not different between active and inactive patients and healthy controls. Percentage of CD4+FOXP3+Treg was lower than healthy controls in clinically active patients but was not different for inactive group and healthy controls. Patients were active when CD4+CD25+FOXP3+Treg was ≤1.19 %, CD4+CD25+Treg was ≤2.68 %, and CD4+FOXP3+Treg was ≤2.60. CD4+CD25+FOXP3+Treg and CD4+FOXP3+Treg were found negatively correlated with disease activity. Peripheral blood regulatory T cells are decreased in clinically active Behçet's disease patients. The advances in our understanding of the interactions between distinct subsets of Treg and clinical activity might help in modulating BD treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912800     DOI: 10.1007/s00296-013-2835-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

Review 1.  Behçet's disease.

Authors:  T Sakane; M Takeno; N Suzuki; G Inaba
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

2.  Decreased percentages of regulatory T cells in peripheral blood of patients with Behcet's disease before ocular attack: a possible predictive marker of ocular attack.

Authors:  Yuki Nanke; Shigeru Kotake; Mari Goto; Hiroshi Ujihara; Masao Matsubara; Naoyuki Kamatani
Journal:  Mod Rheumatol       Date:  2008-04-22       Impact factor: 3.023

Review 3.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

4.  Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease.

Authors:  Guillaume Geri; Benjamin Terrier; Michelle Rosenzwajg; Bertrand Wechsler; Maxime Touzot; Danielle Seilhean; Tu-Anh Tran; Bahram Bodaghi; Lucile Musset; Vassili Soumelis; David Klatzmann; Patrice Cacoub; David Saadoun
Journal:  J Allergy Clin Immunol       Date:  2011-07-02       Impact factor: 10.793

Review 5.  Regulatory T cells in spontaneous autoimmune encephalomyelitis.

Authors:  G C Furtado; D Olivares-Villagómez; M A Curotto de Lafaille; A K Wensky; J A Latkowski; J J Lafaille
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

Review 6.  New insights into the pathogenesis of Behçet's disease.

Authors:  Marc Pineton de Chambrun; Bertrand Wechsler; Guillaume Geri; Patrice Cacoub; David Saadoun
Journal:  Autoimmun Rev       Date:  2011-12-11       Impact factor: 9.754

7.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

Review 8.  Moving to tolerance: clinical application of T regulatory cells.

Authors:  Alicia N McMurchy; Andrew Bushell; Megan K Levings; Kathryn J Wood
Journal:  Semin Immunol       Date:  2011-05-28       Impact factor: 11.130

9.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

10.  A proposed classification of the immunological diseases.

Authors:  Dennis McGonagle; Michael F McDermott
Journal:  PLoS Med       Date:  2006-08       Impact factor: 11.069

View more
  4 in total

1.  [Efficacy and safety of metformin for Behcet's disease and its effect on Treg/Th17 balance: a single-blinded, before-after study].

Authors:  Chen Yong; Luo Dan; Lin Chenhong; Shen Yan; Cai Jianfei; Guan Jianlong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-02-28

Review 2.  Knitting the Threads of Silk through Time: Behçet's Disease-Past, Present, and Future.

Authors:  Fahd Adeeb; Austin G Stack; Alexander D Fraser
Journal:  Int J Rheumatol       Date:  2017-09-10

Review 3.  Regulatory T Cells in Autoimmune Vasculitis.

Authors:  Ke Jin; Simon Parreau; Kenneth J Warrington; Matthew J Koster; Gerald J Berry; Jörg J Goronzy; Cornelia M Weyand
Journal:  Front Immunol       Date:  2022-02-28       Impact factor: 7.561

Review 4.  Immunopathophysiology and clinical impact of uveitis in inflammatory rheumatic diseases: An update.

Authors:  Elvis Hysa; Carlo Alberto Cutolo; Emanuele Gotelli; Greta Pacini; Carlotta Schenone; Elke O Kreps; Vanessa Smith; Maurizio Cutolo
Journal:  Eur J Clin Invest       Date:  2021-05-05       Impact factor: 4.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.